A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.
Benjamin C CreelanTammie C YehSang-We KimNaoyuki NogamiDong-Wan KimLaura Q M ChowShintaro KandaRosemary TaylorWeifeng TangMei TangHelen K AngellMartine P RoudierMarcelo MarottiDon L GibbonsPublished in: British journal of cancer (2020)
Durvalumab and gefitinib in combination had higher toxicity than either agent alone. No significant increase in PFS was detected compared with historical controls. Therefore, concurrent PD-L1 inhibitors with gefitinib should be generally avoided in TKI-naive patients with EGFRm NSCLC.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- locally advanced
- advanced non small cell lung cancer
- tyrosine kinase
- squamous cell carcinoma
- rectal cancer
- hiv infected
- neoadjuvant chemotherapy
- brain metastases
- phase ii study
- radiation therapy
- chronic myeloid leukemia
- oxidative stress
- open label
- randomized controlled trial
- lymph node
- antiretroviral therapy